PE20110568A1 - Agentes terapeuticos 414 - Google Patents
Agentes terapeuticos 414Info
- Publication number
- PE20110568A1 PE20110568A1 PE2011000125A PE2011000125A PE20110568A1 PE 20110568 A1 PE20110568 A1 PE 20110568A1 PE 2011000125 A PE2011000125 A PE 2011000125A PE 2011000125 A PE2011000125 A PE 2011000125A PE 20110568 A1 PE20110568 A1 PE 20110568A1
- Authority
- PE
- Peru
- Prior art keywords
- alkyl
- chloropyridin
- propanamide
- pyrimidin
- atom
- Prior art date
Links
- 239000003814 drug Substances 0.000 title 1
- 229940124597 therapeutic agent Drugs 0.000 title 1
- -1 HYDROXY, CARBOXY, CARBAMOYL Chemical class 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 3
- QLNJFJADRCOGBJ-UHFFFAOYSA-N propionamide Chemical compound CCC(N)=O QLNJFJADRCOGBJ-UHFFFAOYSA-N 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I, DONDE A Y B SON CADA UNO N, CR6; X ES C, N; Y ES CH, N; Z ES C, N; R1 ES ALQUILO C1-C6, ARILO, ARILALQUILO C1-C6, ENTRE OTROS; R2 ES ALQUILO C1-C6 OPCIONALMENTE SUSTITUIDO POR 1-2 HIDROXI, CARBOXI, CARBAMOILO, ENTRE OTROS; R3 ES HETEROARILO MONOCICLICO UNIDO A C DE 5-6 MIEMBROS, QUE CONTIENE UN ATOMO DE N EN LA POSICION 2, HETROARILO BICICLICO UNIDO A C DE 8-10 MIEMBROS QUE CONTIENE UN ATOMO DE NEN LA POSICION 2, ENTRE OTROS; R5 ES H, ALCOXI C1-C4, ALQUILO C1-C4; L ES S, O, NH, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (2S)-N-(5-CLOROPIRIDIN-2-IL)-2-(1-(3-CLOROPIRIDIN-2-IL)-1H-PIRAZOLO[3,2-d]-PIRIMIDIN-4-ILOXI)-3-(3-HIDROXIAZETIDIN-1-IL)PROPANAMIDA; (2S)-2-[1-(2-CLOROFENIL)PIRAZOLO[3,4-d]PIRIMIDIN-4-IL]OXI-N-(5-CLORO-2-PIRIDIL)-3-(3-HIDROXIAZETIDIN-1-IL)PROPANAMIDA; ENTRE OTROS. DICHOS COMPUESTOS SON UTILES EN EL TRATAMIENTO O PREVENCION DE UNA ENFERMEDAD O AFECCION MEDICA MEDIADA POR GLUCOQUINASA (GLK O GK) UTILES EN EL TRATAMIENTO DE DIABETES TIPO 2
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US8591908P | 2008-08-04 | 2008-08-04 | |
| US16804809P | 2009-04-09 | 2009-04-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20110568A1 true PE20110568A1 (es) | 2011-09-07 |
Family
ID=41563374
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2011000125A PE20110568A1 (es) | 2008-08-04 | 2009-08-03 | Agentes terapeuticos 414 |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US8143263B2 (es) |
| EP (1) | EP2324028A2 (es) |
| JP (1) | JP2011529955A (es) |
| KR (1) | KR20110052676A (es) |
| CN (1) | CN102171213A (es) |
| AR (1) | AR072900A1 (es) |
| AU (1) | AU2009278929B2 (es) |
| BR (1) | BRPI0917589A2 (es) |
| CA (1) | CA2732165A1 (es) |
| CL (1) | CL2011000249A1 (es) |
| CO (1) | CO6351730A2 (es) |
| CR (1) | CR20110065A (es) |
| DO (1) | DOP2011000047A (es) |
| EA (1) | EA201100097A1 (es) |
| EC (1) | ECSP11010809A (es) |
| IL (1) | IL210778A0 (es) |
| MX (1) | MX2011001333A (es) |
| PE (1) | PE20110568A1 (es) |
| SV (1) | SV2011003829A (es) |
| TW (1) | TW201011026A (es) |
| UY (1) | UY32032A (es) |
| WO (1) | WO2010015849A2 (es) |
| ZA (1) | ZA201101663B (es) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| TW200714597A (en) * | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| CL2007003061A1 (es) * | 2006-10-26 | 2008-08-01 | Astrazeneca Ab | Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2. |
| GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
| GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| AR076221A1 (es) * | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad |
| AR076220A1 (es) * | 2009-04-09 | 2011-05-26 | Astrazeneca Ab | Derivados de pirazol [4,5 - e] pirimidina |
| US8530413B2 (en) | 2010-06-21 | 2013-09-10 | Sanofi | Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments |
| TW201215387A (en) | 2010-07-05 | 2012-04-16 | Sanofi Aventis | Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament |
| TW201215388A (en) | 2010-07-05 | 2012-04-16 | Sanofi Sa | (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments |
| TW201221505A (en) | 2010-07-05 | 2012-06-01 | Sanofi Sa | Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament |
| WO2013037390A1 (en) | 2011-09-12 | 2013-03-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| EP2760862B1 (en) | 2011-09-27 | 2015-10-21 | Sanofi | 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| CN103450124B (zh) * | 2013-08-30 | 2016-03-09 | 江苏九九久科技股份有限公司 | 决奈达隆合成方法 |
| US10538522B2 (en) | 2015-05-14 | 2020-01-21 | The Regents Of The University Of California | Brassinosteroid mimetics |
| SI3395801T1 (sl) * | 2015-12-16 | 2021-08-31 | Nippon Soda Co., Ltd. | Arilazolna spojina in sredstvo za zatiranje škodljivcev |
| CN106749265A (zh) * | 2016-11-13 | 2017-05-31 | 曹艳 | 一种别嘌醇衍生物及其在制备抗肿瘤药物中的用途 |
| CN106749263A (zh) * | 2016-11-13 | 2017-05-31 | 曹艳 | 一种别嘌醇衍生物及其在制备抗肿瘤药物中的用途 |
| CN106361753A (zh) * | 2016-11-13 | 2017-02-01 | 曹艳 | 一种别嘌醇衍生物及其在制备抗肿瘤药物中的用途 |
| CN106749264A (zh) * | 2016-11-13 | 2017-05-31 | 曹艳 | 一种别嘌醇衍生物及其在制备抗肿瘤药物中的用途 |
| EP3357928B1 (en) | 2017-02-03 | 2021-01-06 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Novel dyes with phosphinic acid, phosphinate, phosphonate and phosphonamidate substituents as auxochromic groups and methods for preparing the same |
| CN108033966A (zh) * | 2018-01-05 | 2018-05-15 | 天津药明康德新药开发有限公司 | 7-叔丁基3-乙基8-甲基5,6二氢三唑并吡嗪3,7(8h)二甲酸基酯的合成方法 |
| EP3986853A1 (en) | 2019-06-19 | 2022-04-27 | NMD Pharma A/S | Compounds for the treatment of neuromuscular disorders |
| CN113185520A (zh) * | 2021-04-28 | 2021-07-30 | 山东鲁抗医药股份有限公司 | 替格瑞洛杂质b及其制备方法 |
Family Cites Families (99)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2750393A (en) * | 1954-12-01 | 1956-06-12 | Sterling Drug Inc | Iodinated 5-henzamidotetrazoles and preparation thereof |
| US2967194A (en) * | 1958-05-15 | 1961-01-03 | Pennsalt Chemicals Corp | 4-trifluoromethylsalicylamides |
| FR1526074A (fr) | 1967-03-22 | 1968-05-24 | Rech S Ind S O R I Soc D | Méthoxy-phényl-amino-2-thiazoles, leurs amides et leurs procédés de préparation |
| FR2088019A1 (en) | 1970-05-08 | 1972-01-07 | Rabot Ets David | Esters of 2 and 6-substituted nicotinic acids - with vasomotor active |
| GB1352415A (en) | 1970-05-03 | 1974-05-08 | Boots Co Ltd | Esters of substituted nicotine acids |
| CS173097B1 (es) | 1972-12-01 | 1977-02-28 | ||
| GB1400540A (en) * | 1972-12-06 | 1975-07-16 | Smith Kline French Lab | Salicylamides and compositions thereof |
| US4009174A (en) * | 1972-12-08 | 1977-02-22 | The Boots Company Limited | Esters of substituted nicotinic acids |
| GB1437800A (en) * | 1973-08-08 | 1976-06-03 | Phavic Sprl | Derivatives of 2-benzamido-5-nitro-thiazoles |
| GB1561350A (en) | 1976-11-05 | 1980-02-20 | May & Baker Ltd | Benzamide derivatives |
| FR2344284A1 (fr) * | 1976-03-17 | 1977-10-14 | Cerm Cent Europ Rech Mauvernay | Nouveaux composes tricycliques a cycle furannique et leur application comme antidepresseurs |
| GB1588242A (en) | 1977-10-28 | 1981-04-23 | May & Baker Ltd | N-(tetrazol-5-yl)-salicylamide derivatives |
| US4474792A (en) * | 1979-06-18 | 1984-10-02 | Riker Laboratories, Inc. | N-Tetrazolyl benzamides and anti-allergic use thereof |
| FR2493848B2 (fr) * | 1980-11-07 | 1986-05-16 | Delalande Sa | Nouveaux derives des nor-tropane et granatane, leur procede de preparation et leur application en therapeutique |
| JPS59139357A (ja) | 1983-01-28 | 1984-08-10 | Torii Yakuhin Kk | アミジン誘導体 |
| JPS62142168A (ja) | 1985-10-16 | 1987-06-25 | Mitsubishi Chem Ind Ltd | チアゾ−ル誘導体及びそれを有効成分とするロイコトリエンきつ抗剤 |
| CA1327358C (en) | 1987-11-17 | 1994-03-01 | Morio Fujiu | Fluoro cytidine derivatives |
| JP2852659B2 (ja) | 1988-03-03 | 1999-02-03 | 富山化学工業株式会社 | ピペラジン誘導体およびその塩 |
| DE3822449A1 (de) | 1988-07-02 | 1990-01-04 | Henkel Kgaa | Oxidationshaarfaerbemittel mit neuen kupplern |
| GB9015764D0 (en) * | 1990-07-18 | 1990-09-05 | Fujisawa Pharmaceutical Co | Pyrazolopyridine compound and processes for preparation thereof |
| US5466715A (en) * | 1991-12-31 | 1995-11-14 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
| US5258407A (en) | 1991-12-31 | 1993-11-02 | Sterling Winthrop Inc. | 3,4-disubstituted phenols-immunomodulating agents |
| US5273986A (en) | 1992-07-02 | 1993-12-28 | Hoffmann-La Roche Inc. | Cycloalkylthiazoles |
| EP0619116A3 (en) | 1993-04-05 | 1994-11-23 | Hoechst Japan | Use of synthetic retinoids for osteopathy. |
| GB9307527D0 (en) | 1993-04-13 | 1993-06-02 | Fujisawa Pharmaceutical Co | New venzamide derivatives,processes for the preparation thereof and pharmaceutical composition comprising the same |
| US5661153A (en) | 1994-07-19 | 1997-08-26 | Japan Energy Corporation | 1-arylpyrimidine derivatives and pharmaceutical use thereof |
| US5510478A (en) * | 1994-11-30 | 1996-04-23 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| US5672750A (en) * | 1994-12-16 | 1997-09-30 | Eastman Chemical Company | Preparation of aromatic amides from carbon monoxide, an amine and an aromatic chloride |
| US5849735A (en) * | 1995-01-17 | 1998-12-15 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| US5712270A (en) | 1995-11-06 | 1998-01-27 | American Home Products Corporation | 2-arylamidothiazole derivatives with CNS activity |
| DK0841339T3 (da) * | 1996-11-06 | 2007-07-02 | Basilea Pharmaceutica Ag | Vinylpyrrolidinon-cephalosporinderivater |
| AUPO395396A0 (en) * | 1996-12-02 | 1997-01-02 | Fujisawa Pharmaceutical Co., Ltd. | Benzamide derivatives |
| FR2757852B1 (fr) | 1996-12-31 | 1999-02-19 | Cird Galderma | Composes stilbeniques a groupement adamantyl, compositions les contenant et utilisations |
| US6245817B1 (en) * | 1997-02-14 | 2001-06-12 | Bayer Corporation | NPY5 receptor antagonists and methods for using same |
| EP0910565A1 (en) * | 1997-02-14 | 1999-04-28 | Bayer Corporation | Amide derivatives as selective neuropeptide y receptor antagonists |
| EP1000932B9 (en) * | 1997-06-27 | 2005-12-28 | Fujisawa Pharmaceutical Co., Ltd. | Aromatic ring derivatives |
| EP0995742A4 (en) * | 1997-06-27 | 2004-08-25 | Fujisawa Pharmaceutical Co | SULPHONAMIDE COMPOUNDS AND THEIR MEDICAL USE |
| US6613942B1 (en) | 1997-07-01 | 2003-09-02 | Novo Nordisk A/S | Glucagon antagonists/inverse agonists |
| US6114483A (en) | 1997-08-27 | 2000-09-05 | E. I. Du Pont De Nemours And Company | Polymerization of olefins |
| CA2309331A1 (en) | 1997-11-12 | 1999-05-20 | Institute Of Medicinal Molecular Design, Inc. | Agent acting on retinoid receptor |
| GB9725298D0 (en) | 1997-11-28 | 1998-01-28 | Zeneca Ltd | Insecticidal thiazole derivatives |
| ES2317688T3 (es) | 1998-01-29 | 2009-04-16 | Amgen Inc. | Moduladores ppar-gamma. |
| DE19816780A1 (de) | 1998-04-16 | 1999-10-21 | Bayer Ag | Substituierte 2-Oxo-alkansäure-[2-(indol-3-yl)-ethyl]amide |
| GB9811969D0 (en) | 1998-06-03 | 1998-07-29 | Celltech Therapeutics Ltd | Chemical compounds |
| US6197798B1 (en) * | 1998-07-21 | 2001-03-06 | Novartis Ag | Amino-benzocycloalkane derivatives |
| JP4191825B2 (ja) | 1998-09-10 | 2008-12-03 | あすか製薬株式会社 | 5−アミノイソキサゾール誘導体 |
| US6320050B1 (en) * | 1999-03-29 | 2001-11-20 | Hoffmann-La Roche Inc. | Heteroaromatic glucokinase activators |
| RU2242469C2 (ru) | 1999-03-29 | 2004-12-20 | Ф.Хоффманн-Ля Рош Аг | Активаторы глюкокиназы |
| US6610846B1 (en) | 1999-03-29 | 2003-08-26 | Hoffman-La Roche Inc. | Heteroaromatic glucokinase activators |
| AU1917201A (en) | 1999-11-18 | 2001-05-30 | Centaur Pharmaceuticals, Inc. | Amide therapeutics and methods for treating inflammatory bowel disease |
| CA2401778C (en) | 2000-02-29 | 2010-12-21 | Cor Therapeutics, Inc. | Benzamides and related inhibitors of factor xa |
| EP1132381A1 (en) | 2000-03-08 | 2001-09-12 | Cermol S.A. | Ester derivatives of dimethylpropionic acid and pharmaceutical compositions containing them |
| US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| ES2233660T3 (es) | 2000-05-03 | 2005-06-16 | F. Hoffmann-La Roche Ag | Activadores de glucokinasa alquinil fenil heteroaromaticos. |
| MXPA03003572A (es) | 2000-11-22 | 2003-07-14 | Yamanouchi Pharma Co Ltd | Derivados de benceno sustituidos o sales de los mismos. |
| DK1341774T3 (da) | 2000-12-06 | 2006-06-12 | Hoffmann La Roche | Kondenserede heteroaromatiske glucokinase-aktivatorer |
| WO2002051397A1 (en) | 2000-12-22 | 2002-07-04 | Ishihara Sangyo Kaisha, Ltd. | Aniline derivatives or salts thereof and cytokine production inhibitors containing the same |
| US20040077697A1 (en) | 2001-02-02 | 2004-04-22 | Hiroyuki Koshio | 2-Acylaminothiazole derivative or its salt |
| SE0102300D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| SE0102299D0 (sv) | 2001-06-26 | 2001-06-26 | Astrazeneca Ab | Compounds |
| PL368129A1 (en) | 2001-08-09 | 2005-03-21 | Ono Pharmaceutical Co, Ltd. | Carboxylic acid derivative compounds and drugs comprising these compounds as the active ingredient |
| SE0102764D0 (sv) | 2001-08-17 | 2001-08-17 | Astrazeneca Ab | Compounds |
| EP1336607A1 (en) | 2002-02-19 | 2003-08-20 | Novo Nordisk A/S | Amide derivatives as glucokinase activators |
| DE10161765A1 (de) | 2001-12-15 | 2003-07-03 | Bayer Cropscience Gmbh | Substituierte Phenylderivate |
| US6911545B2 (en) | 2001-12-19 | 2005-06-28 | Hoffman-La Roche Inc. | Crystals of glucokinase and methods of growing them |
| DE60328671D1 (de) | 2002-03-26 | 2009-09-17 | Banyu Pharma Co Ltd | Neue aminobenzamidderivate |
| WO2004007472A1 (ja) | 2002-07-10 | 2004-01-22 | Ono Pharmaceutical Co., Ltd. | Ccr4アンタゴニストおよびその医薬用途 |
| GB0226931D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| GB0226930D0 (en) | 2002-11-19 | 2002-12-24 | Astrazeneca Ab | Chemical compounds |
| MXPA05009059A (es) | 2003-02-26 | 2005-10-19 | Banyu Pharma Co Ltd | Derivados de heteroarilcarbamoilbenceno. |
| EP2385040A1 (en) | 2003-03-14 | 2011-11-09 | ONO Pharmaceutical Co., Ltd. | Nitrogen-containing heterocyclic derivatives and drugs containing the same as the active ingredient |
| GB0325402D0 (en) | 2003-10-31 | 2003-12-03 | Astrazeneca Ab | Compounds |
| US20050165031A1 (en) | 2003-11-13 | 2005-07-28 | Ambit Biosciences Corporation | Urea derivatives as ABL modulators |
| EP1532980A1 (en) | 2003-11-24 | 2005-05-25 | Novo Nordisk A/S | N-heteroaryl indole carboxamides and analogues thereof, for use as glucokinase activators in the treatment of diabetes |
| GB0327761D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| GB0327760D0 (en) | 2003-11-29 | 2003-12-31 | Astrazeneca Ab | Compounds |
| GB0328178D0 (en) | 2003-12-05 | 2004-01-07 | Astrazeneca Ab | Compounds |
| KR20060105872A (ko) | 2003-12-29 | 2006-10-11 | 반유 세이야꾸 가부시끼가이샤 | 신규한 2-헤테로아릴 치환된 벤즈이미다졸 유도체 |
| JP2007523142A (ja) * | 2004-02-18 | 2007-08-16 | アストラゼネカ アクチボラグ | ベンズアミド誘導体、およびグルコキナーゼ活性化物質としてのそれらの使用 |
| AU2005214137B2 (en) | 2004-02-18 | 2008-05-29 | Astrazeneca Ab | Compounds |
| TW200600086A (en) * | 2004-06-05 | 2006-01-01 | Astrazeneca Ab | Chemical compound |
| WO2006030925A1 (ja) | 2004-09-13 | 2006-03-23 | Ono Pharmaceutical Co., Ltd. | 含窒素複素環誘導体およびそれらを有効成分とする薬剤 |
| GB0423044D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| KR20070085371A (ko) | 2004-10-16 | 2007-08-27 | 아스트라제네카 아베 | 페녹시 벤즈아미드 화합물의 제조 방법 |
| GB0423043D0 (en) | 2004-10-16 | 2004-11-17 | Astrazeneca Ab | Compounds |
| CA2605738C (en) | 2005-04-25 | 2013-10-01 | Merck Patent Gesellschaft Mit Beschraenkter Haftung | Novel azaheterocyclic compounds as kinase inhibitors |
| EP1891069A1 (en) * | 2005-05-24 | 2008-02-27 | AstraZeneca AB | 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators |
| TW200714597A (en) | 2005-05-27 | 2007-04-16 | Astrazeneca Ab | Chemical compounds |
| WO2007007040A1 (en) * | 2005-07-09 | 2007-01-18 | Astrazeneca Ab | 2 -heterocyclyloxybenzoyl amino heterocyclyl compounds as modulators of glucokinase for the treatment of type 2 diabetes |
| KR101346902B1 (ko) | 2005-07-09 | 2014-01-02 | 아스트라제네카 아베 | 당뇨병 치료에 있어 glk 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체 |
| US20080234273A1 (en) | 2005-07-09 | 2008-09-25 | Mckerrecher Darren | Heteroaryl Benzamide Derivatives for Use as Glk Activators in the Treatment of Diabetes |
| US20090105263A1 (en) | 2005-09-16 | 2009-04-23 | Peter William Rodney Caulkett | Heterobicyclic compounds as glucokinase activators |
| TW200738621A (en) | 2005-11-28 | 2007-10-16 | Astrazeneca Ab | Chemical process |
| US8003642B2 (en) * | 2006-03-10 | 2011-08-23 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| TW200825063A (en) * | 2006-10-23 | 2008-06-16 | Astrazeneca Ab | Chemical compounds |
| CL2007003061A1 (es) | 2006-10-26 | 2008-08-01 | Astrazeneca Ab | Compuestos derivados de 3,5-dioxi-benzamida; proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso para tratar una enfermedad mediada a traves de glk, tal como la diabetes tipo 2. |
| US20100094009A1 (en) | 2006-12-21 | 2010-04-15 | Mccabe James | Novel crystalline compound useful as glk activator |
| GB0902406D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Crystalline polymorphic form |
| GB0902434D0 (en) * | 2009-02-13 | 2009-04-01 | Astrazeneca Ab | Chemical process |
-
2009
- 2009-08-03 WO PCT/GB2009/050970 patent/WO2010015849A2/en not_active Ceased
- 2009-08-03 MX MX2011001333A patent/MX2011001333A/es not_active Application Discontinuation
- 2009-08-03 CA CA2732165A patent/CA2732165A1/en not_active Abandoned
- 2009-08-03 JP JP2011521643A patent/JP2011529955A/ja not_active Withdrawn
- 2009-08-03 EP EP09785441A patent/EP2324028A2/en not_active Withdrawn
- 2009-08-03 BR BRPI0917589A patent/BRPI0917589A2/pt not_active IP Right Cessation
- 2009-08-03 PE PE2011000125A patent/PE20110568A1/es not_active Application Discontinuation
- 2009-08-03 KR KR1020117004895A patent/KR20110052676A/ko not_active Withdrawn
- 2009-08-03 CN CN2009801395833A patent/CN102171213A/zh active Pending
- 2009-08-03 EA EA201100097A patent/EA201100097A1/ru unknown
- 2009-08-03 AR ARP090102973A patent/AR072900A1/es unknown
- 2009-08-03 AU AU2009278929A patent/AU2009278929B2/en not_active Expired - Fee Related
- 2009-08-04 UY UY0001032032A patent/UY32032A/es not_active Application Discontinuation
- 2009-08-04 US US12/535,293 patent/US8143263B2/en not_active Expired - Fee Related
- 2009-08-04 TW TW098126200A patent/TW201011026A/zh unknown
-
2011
- 2011-01-20 IL IL210778A patent/IL210778A0/en unknown
- 2011-02-01 CO CO11011423A patent/CO6351730A2/es not_active Application Discontinuation
- 2011-02-04 CL CL2011000249A patent/CL2011000249A1/es unknown
- 2011-02-04 SV SV2011003829A patent/SV2011003829A/es not_active Application Discontinuation
- 2011-02-04 CR CR20110065A patent/CR20110065A/es unknown
- 2011-02-04 DO DO2011000047A patent/DOP2011000047A/es unknown
- 2011-02-04 EC EC2011010809A patent/ECSP11010809A/es unknown
- 2011-03-03 ZA ZA2011/01663A patent/ZA201101663B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DOP2011000047A (es) | 2011-02-28 |
| AU2009278929A8 (en) | 2011-03-10 |
| WO2010015849A2 (en) | 2010-02-11 |
| CL2011000249A1 (es) | 2011-07-15 |
| AU2009278929B2 (en) | 2012-07-05 |
| AU2009278929A1 (en) | 2010-02-11 |
| US20100093757A1 (en) | 2010-04-15 |
| WO2010015849A3 (en) | 2010-04-01 |
| UY32032A (es) | 2010-03-26 |
| CA2732165A1 (en) | 2010-02-11 |
| US8143263B2 (en) | 2012-03-27 |
| CO6351730A2 (es) | 2011-12-20 |
| ZA201101663B (en) | 2011-11-30 |
| BRPI0917589A2 (pt) | 2015-11-17 |
| CN102171213A (zh) | 2011-08-31 |
| SV2011003829A (es) | 2011-07-01 |
| MX2011001333A (es) | 2011-03-15 |
| CR20110065A (es) | 2011-05-10 |
| IL210778A0 (en) | 2011-03-31 |
| AR072900A1 (es) | 2010-09-29 |
| TW201011026A (en) | 2010-03-16 |
| KR20110052676A (ko) | 2011-05-18 |
| ECSP11010809A (es) | 2011-03-31 |
| EA201100097A1 (ru) | 2011-10-31 |
| EP2324028A2 (en) | 2011-05-25 |
| JP2011529955A (ja) | 2011-12-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PE20110568A1 (es) | Agentes terapeuticos 414 | |
| PE20070136A1 (es) | COMPUESTOS DERIVADOS DE N-(PIRIDIN-2-IL)-SULFONAMIDA COMO INHIBIDORES DE LA ENZIMA 11-beta-HIDROXIESTEROIDE DESHIDROGENASA HUMANA TIPO 1 | |
| SE0200979D0 (sv) | New compounds | |
| PE20130602A1 (es) | Derivados de 6-cicloalquil-1,5-dihidro-pirazolo(3,4-d)pirimidin-4-onas y su uso como inhibidores de pde9a | |
| JO2650B1 (en) | Solid product | |
| NO20052914L (no) | Terapeutiske forbindelser | |
| PE20120620A1 (es) | Dihidropirazolonas sustituidas como inhibidores de hif-propil-4-hidroxilasas | |
| MY151295A (en) | Pyrimidyl indoline compound | |
| TN2009000199A1 (en) | Heteromonocyclic compound and use thereof | |
| SI2091948T1 (sl) | Novi inhibitorji glutaminil ciklaze | |
| PE20110285A1 (es) | Derivados de sulfonamidofenil propionamida como ligandos del receptor vaniloide del subtipo 1 | |
| PE20110136A1 (es) | Compuestos organicos | |
| TW200800957A (en) | New compounds | |
| ATE356621T1 (de) | (s)-2-n-propylamino-5-hydroxytetralin als d3- agonistisches therapeutikum | |
| ATE431345T1 (de) | Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate | |
| AR053554A1 (es) | Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos | |
| PE20061394A1 (es) | Metabolitos de n-(2-cloro-6-metilfenil)-2-[[6-[4-(2-hidroxietil)-1-piperazinil]-2-metil-4-pirimidinil]amino]-5-tiazolcarboxamidas | |
| PE20110773A1 (es) | Tetrahidropiran espiro pirrolidinona y piperidinona sustituidas, y su preparacion | |
| MY158069A (en) | Tricyclic compound and pharmaceutical use thereof | |
| NO20064982L (no) | 1,3,4-oksadiazol-2-oner som PPAR delta modulatorer og anvendelse derav | |
| EA200971003A1 (ru) | Бициклическое соединение и его фармацевтическое применение | |
| PE20090445A1 (es) | Inhibidores de produccion de beta amiloide | |
| NO20076037L (no) | Nye tiazolidinoner uten basisk nitrogen, deres fremstilling og anvendelse som farmasoytiske midler | |
| EA200970615A1 (ru) | Соединения имидазолидинониламинопиримидина для лечения рака | |
| CY1108241T1 (el) | Πυριδυλσουλφοναμιδο πυριμιδινες για την θεραπεια της διαβητικης νεφροπαθειας |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |